Viatris Interest Expense | VTRS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Viatris

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
471 M	550 M	573 M	592 M	636 M	498 M	517 M	542 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
636 M	471 M	548 M

Quarterly Interest Expense Viatris

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
121 M	120 M	120 M	117 M	116 M	146 M	146 M	138 M	142 M	144 M	147 M	-	153 M	146 M	146 M	-	152 M	167 M	169 M	-	117 M	116 M	120 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
169 M	116 M	137 M

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Bausch Health Companies BHC	-142 M	$ 5.89	1.55 %	$ 2.18 B	Canada
Canopy Growth Corporation CGC	38.2 M	$ 0.88	1.04 %	$ 262 M	Canada
China Pharma Holdings CPHI	27.3 K	$ 0.65	1.57 %	$ 2.79 M	China
Cumberland Pharmaceuticals CPIX	496 K	$ 7.09	0.27 %	$ 105 M	USA
Cronos Group CRON	-241 K	$ 3.25	0.78 %	$ 1.25 B	Canada
Emergent BioSolutions EBS	54.2 M	$ 7.24	14.29 %	$ 387 M	USA
Evolus EOLS	-539 K	$ 7.47	4.62 %	$ 482 M	USA
Harrow Health HROW	47 K	$ 30.58	0.33 %	$ 1.12 B	USA
Organogenesis Holdings ORGO	-5 K	$ 1.29	2.19 %	$ 163 M	USA
Pacira BioSciences PCRX	-6.62 M	$ 25.05	0.42 %	$ 1.12 B	USA
Perrigo Company plc PRGO	-13.2 M	$ 14.44	1.3 %	$ 2 B	USA
Relmada Therapeutics RLMD	5.15 M	$ 3.48	0.68 %	$ 137 M	USA
Rockwell Medical RMTI	-623 K	$ 8.23	0.93 %	$ 296 M	USA
SCYNEXIS SCYX	3.13 M	$ 5.03	1.07 %	$ 251 M	USA
Solid Biosciences SLDB	824 K	$ 7.06	3.07 %	$ 618 M	USA
Sundial Growers SNDL	81 K	$ 1.25	0.81 %	$ 323 M	Canada
Sonoma Pharmaceuticals SNOA	16 K	$ 1.22	0.81 %	$ 2.05 M	USA
Tilray TLRY	41.3 M	$ 3.72	3.05 %	$ 3.31 B	Canada
TherapeuticsMD TXMD	300 K	$ 2.01	1.46 %	$ 23.3 M	USA
Veru VERU	768 K	$ 2.55	1.59 %	$ 37.3 M	USA
cbdMD YCBD	34.3 K	$ 0.43	0.29 %	$ 1.73 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
Adamis Pharmaceuticals Corporation ADMP	6.65 K	-	0.86 %	$ 117 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
Zynerba Pharmaceuticals ZYNE	27 K	-	-	$ 55.5 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
Evoke Pharma EVOK	501 K	-	-	$ 36.6 M	USA
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	2.4 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
AcelRx Pharmaceuticals ACRX	134 K	-	7.5 %	$ 6.35 M	USA
Assertio Holdings ASRT	2.78 M	-	-	$ 150 M	USA
Jupiter Wellness JUPW	152 K	-	-	$ 33.6 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
ProPhase Labs PRPH	-174 K	-	-	$ 5.07 M	USA